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Characterization of Cannabinoid Receptor 2 Transcript Expression in 
B Cells 
Tracy Sherwood 
ABSTRACT 
 
Cannabinoids and cannabinoid receptors have been shown to 
play important roles in immune regulation particularly as modulators 
of anti-inflammatory cytokines and antibody production. The 
predominant cannabinoid receptor involved in this immune regulation 
is cannabinoid receptor 2 (CB2), which is robustly expressed in B cells. 
Utilizing a combination of bioinformatics, 5' RACE, real time RT-qPCR, 
and reporter assays, we showed that human B cells from peripheral 
blood mononuclear cells (PBMC) expressed one CB2 transcript while 
mouse B cells from spleen express three CB2 transcripts. Alignment of 
the sequenced B cell RACE products to either the mouse or human 
genome, along with the GenBank mRNA sequences, revealed that the 
transcripts isolated in this study contained previously unidentified 
transcriptional start sites (TSSs). In addition, expression construct 
testing of the genomic region containing the TSSs of the mouse CB2 
exon 1 and 2 transcripts showed a significant increase of promoter 
viii 
activity. Bioinformatics analysis for cis-sequences in the promoter 
regions identified DNA binding sites for NF-kB, STAT6, and Elk1 
transcription factors activated by LPS, IL-4 and anti-CD40. Regarding 
variations in CB2 transcript expression among the immune cell 
subtypes, RACE analysis showed that the exon 1b transcript is seen in 
B cells but not in T cells, dendritic cells or macrophages. Furthermore, 
RT-qPCR showed variations in transcript expression during B cell 
development as well as in resting versus LPS or IL-4/anti-CD40 
stimulated B cells. The exon 1a transcript was predominant in pre-, 
immature and resting B cells whereas the exon 1b and 2 transcripts 
were enhanced in mature and activated B cells. These data showed for 
the first time that human B cells use one TSS for CB2 expression while 
mouse B cells use multiple TSSs for the expression of three CB2 
transcripts, in which the expression of the individual transcript is 
related to immune cell type and/or cell activation state. Additionally, 
this is the first report in mouse B cells defining TSSs that are in 
genomic areas with promoter activity thus suggesting the location of 
two promoter regions. Defining the CB2 transcript expression during 
various stages of B cell activation provide clues to therapeutic 
methods. 
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INTRODUCTION 
 
Cannabinoids and Cannabinoid Receptors 
  The marijuana plant (Cannabis sativa) and preparations derived 
from it have been used for medicinal and recreational purposes for 
thousands of years. Cannabis produces ~60 unique compounds known 
as cannabinoids, of which Δ9-tetrahydrocannabinol (THC) is considered 
the most important, owing to its abundance and psychoactive 
component (4, 29). Currently two cannabinoid receptors have been 
described. Cannabinoid receptor 1 (CB1) the first to be identified (27), 
also known as the “central” cannabinoid receptor is found primarily in 
the brain and central nervous system (CNS) and is responsible for the 
psychoactive effect of THC. CB1 is also found in cells of the male and 
female reproductive system, as well as in some peripheral organs, 
such as liver, fat and muscle cells. Cannabinoid receptor 2 (CB2) (30), 
known as the “peripheral” cannabinoid receptor is almost exclusively 
found in the immune system, with highest expression observed in B 
cells. It is also found in the peripheral nervous system and in 
microglia. CB2 has been shown to be the cannabinoid receptor 
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primarily responsible for the anti-inflammatory and possible immune 
therapeutic effects of cannabis (22) (38) (7).  
 The cannabinoid receptors belong to the G protein-coupled 
receptor (GPCR) superfamily, and are seven-transmembrane domain 
receptors, which act as a guanine nucleotide exchange factor (GEF) for 
associated G-proteins by exchanging bound GDP for GTP. The bound 
GTP activates the G-protein by causing the dissociation of the G-
protein’s α-subunit from the β and γ subunits. Two signal transduction 
pathways are affected by G-protein activation, the cAMP pathway and 
the phosphatidylinositol pathway. Cannabinoid receptors signal 
through a Gi/o-protein, in which dissociation of the α-subunit inhibits 
adenylate cyclase and thereby decreasing the production of cyclic AMP 
(19) (18) (2). 
 The cannabinoid receptors are activated by three general types 
of cannabinoids: 1. Phytocannabinoids, also known as the classical 
cannabinoids, which 66 have been isolated from Cannabis. 2. 
Endocannabinoids, produced endogenously by the body, in which two 
have been well characterized, arachidonolyethanolamine (Anandamide 
or AEA) and 2-arachidonynoyl glycerol (2-AG) endogenous. 3. 
Synthetic cannabinoids that are useful in experiments to determine 
receptor function. Numerous agonists have been design, some non-
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selective, such as CP-55940, that bind CB1 and CB2 with similar 
affinity, as well as selective agonists, such as JWH-133, which binds 
only to CB2. In addition, antagonists have been designed to either 
selectively block CB1, SR141716, or CB2, SR144528  (38) (24, 29, 31) 
(6).   
  
B cells 
 B cells are antibody producing lymphocytes (white blood cells) 
that make up part of the adaptive immune system and responsible for 
the humoral immune response, the portion of immunity that is 
mediated by antibodies. On the surface of every B cell is a membrane-
bound immunoglobulin (Ig) receptor, the B cell receptor (BCR), which 
binds to specific antigen. It is the BCR and the ability of the receptor to 
recognize antigen in its native form, as well as the maturation and 
production of large amounts of antibodies that distinguishes B cells 
from other types of lymphocytes. The “B” comes for the bursa of 
Fabricius, an organ in birds that is the site of hematopoiesis and B cell 
development and maturation. In mammals, the bone marrow is the 
site of hematopoiesis and where B cells are continually produced. 
Development occurs through several stages, each stage representing a 
change in the genome content at the Ig loci (Table 1). At the 
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immature stage B cells migrate to the spleen where the final stage of 
maturation occurs (3). Mature B cells express both surface IgM and 
IgD and are considered naïve until activated by antigen, which can 
occur either in a T cell-dependent or –independent manner(15).  
 The BCR and secreted antibody are comprised of four 
polypeptide chains, two identical heavy and two identical light chains 
with both constant (C) and variable (V) regions. In the heavy chain V 
region there are three segments; Variable (V), Diversity (D), and 
Joining (J), whereas light chain only contains V and J. Germ line DNA 
has up to 200 V genes, twelve D genes, and four J genes, which during  
B cell development randomly rearrange and recombine by a 
mechanism known as VDJ recombination to produce functional VDJ 
genes. The kappa (κ) and lambda (λ) chains of the Ig light chain loci 
rearrange similarly, except the light chain lacks a D gene. The first 
step of recombination for the light chain involves joining of V and J to 
give VJ before the addition C during transcription (14). Translation of 
the spliced mRNA for either Κ or λ results in formation of either the Igκ 
or Igλ light chain. At this point, the mature B cell is considered naïve 
until it is activated by antigen.  
 The five classes of antibody; IgA, IgD, IgE, IgG and IgM 
respectfully, are defined by the constant regions of the Ig heavy chain. 
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Upon exposure to antigen, naïve mature B cells are activated in the 
absence of T cell help (T cell-independent) by antigen cross-linking 
(48) of the IgM BCR and differentiate into functional IgM secreting 
plasma B cells (primary response). However, most antigens are T cell-
dependent and require T cell help for maximum antibody production. 
Antigen primed TH2 helper cells activate B cells through T cell Receptor 
(TCR) recognition of specific antigen presented on B cell MHC II, along 
with co-stimulation of CD40 on B cells by CD40 ligand on T cells (34). 
Cytokines are then secreted by T cells that bind to cytokine receptors 
on B cells and trigger B cell proliferation and differentiation into 
plasma and memory B cells. In addition, some of the functionally 
responsive IgM and IgD expressing mature B cells will undergo the 
process of Ig Class Switch Recombination (CSR) (46), in which 
rearrangement of the DNA places the recombined VDJ gene next to 
either IgG, IgE or IgA C gene, to produce Ig isotype specific secreting 
plasma and memory B cells (9). Each isotype has a distinct function, 
therefore the type of antigen and cytokines present in the B cell 
environment will determine which Ig isotype will be expressed in the 
differentiated plasma and memory B cells (Table 2). The memory B 
cells, formed from activated B cells, have BCRs that are antigen 
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specific so when exposed to the same antigen, a rapid and effective 
immune response occurs (secondary response) (45). 
 
 
 Table 1. B cell Developmental Stages. 
Stage Heavy Chain Light Chain Ig 
Progenitor   Germline germline - 
Early Pro D-J rearrangement germline - 
Late Pro V-DJ rearrangement germline - 
Large Pre VDJ rearranged germline IgM in cytoplasm 
Small Pre VDJ rearranged V-J rearrangement IgM in cytoplasm 
Immature VDJ rearranged VJ rearranged Surface IgM 
Mature VDJ rearranged VJ rearranged Surface IgM & IgD 
 
 
 
Table 2. Cytokines responsible for Ig class switching in mouse 
T cell Cytokine 
Ig isotypes 
IgG1 IgG2a IgG2b IgG3 IgA IgE 
TH2 
IL-4 +     + 
IL-5     +  
TH1 IFNγ  +     
Treg TGFβ   +  +  
 +, indicates Ig that cytokine induces switching from IgM  
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Cannabinoid Effects on B cells  
The molecular events of the peripheral cannabinoid receptor 
(CB2) in immune cell function are still not fully understood. Nor are the 
mechanisms that regulate the CB2 gene, Cnr2, during activation of 
immune cells. CB2 message expression shows a pattern of mRNA 
expression that is most abundant in B cells followed by macrophages 
and then T cells (16, 25). Evidence also suggests that anti-CD40 (25), 
as well as IL-4 through activation of STAT6 (42), up regulate CB2 
message expression and that LPS (25)  down regulates its message 
expression in B cells; however the mechanisms are still unclear. 
Furthermore, CB2 has been implicated in B cell differentiation (8), 
migration (20, 39), proliferation (1, 13) and immunoglobulin isotype 
switching (1). These findings suggest a role of CB2 as an 
immunomodulator. However, many gaps still exist in our 
understanding of this receptor’s role in immune cell function, and in 
particular how is CB2 receptor expression regulated in B cells.  
 
Gene Regulation 
 The modern working definition of a gene is “a locatable 
region of genomic sequence, corresponding to a unit of inheritance, 
which is associated with regulatory regions, transcribed regions, and 
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or other functional sequence regions” (35, 36). A gene is basically a 
DNA sequence that contains the instructions for the production of a 
protein. The basic gene structure consists of a promoter regulatory 
region, and a transcribe region of exons (coding sequences) and 
introns (non-coding sequences) (40). Transcription is the first step 
leading to gene expression resulting in messenger RNA (mRNA), which 
is translated into protein (28). During transcription of a gene, the DNA 
sequence is targeted by RNA polymerase II (Pol II), which produces a 
complementary pre-mRNA strand, except that uracil (U) is used 
instead of thymine (T). The pre-mRNA strand is then spliced to form 
the mature mRNA strand that transports to the cytoplasm to be 
translated into protein. This process of DNA to RNA to protein is known 
as the “central dogma” of biology (Figure 1) (11). 
 
Figure 1. The “Central Dogma” of Biology. Several steps are involved in 
gene expression of a protein. Promoters and enhancers regulate what DNA 
sequence will be transcribed into pre-mRNA, which is then spliced into mRNA 
and translated into protein. This figure was obtained with permission from 
Wikimedia Commons.  
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The promoter is typically upstream adjacent to the gene and 
contains specific DNA cis-sequences, which provide binding sites for 
RNA Pol II and transcription factors (trans-factors). The promoter 
consists of two interacting components, the core promoter and the 
proximal promoter (51).  The core promoter sequence is the minimal 
region of DNA required for Pol II to assemble with the basic trans-
factors and form the pre-initiation complex for initiation of activator-
independent (basal) transcription (17, 43). At the center of the core 
promoter sequence is the initiator (INR) sequence that contains the 
transcription start site (TSS), which is defined as the most 5’ 
nucleotide of mRNA transcribed by Pol II (17, 41). The core promoter 
also contains the cis-sequences for the basic trans-factor elements, 
such as the TATA-box, the TFIIB recognition element (BRE) and the 
downstream promoter element (DPE), in which the TSS (+1) 
designates their position (Figure 2, provided by Wikimedia Commons) 
(43) (21). Cis-sequences upstream of the TSS are negative numbers 
counting back from -1, whereas downstream cis-sequences are 
positive numbers counting from the TSS (+1). The proximal promoter 
is the region generally upstream of the gene that contains regulatory 
elements involved in increasing transcription. These regulatory 
elements, also known as enhancers/repressors, can be several 
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kilobases (kb) away from the TSS. The large protein transcriptional 
complex, causes the DNA to bend back allowing for the placement of 
regulatory sequences far from the TSS (51).  
 
BREu BREdTATA INR DPE
-2 to +5
+1
+28 to +34-31 to -24 -23 to -17-38 to -32
 
Figure 2. The Basic Core Promoter Elements.  BRE, TFIIB recognition 
element, u upstream, d downstream TATA-box; DPE, downstream promoter 
element; INR, initiator; TATA, TATA-box 
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PROJECT SIGNIFICANCE 
 
For centuries marijuana has been used recreationally and as a 
therapeutic for many ailments. However, little research was done 
investigating the beneficial medical effects of marijuana, until the 
discovery of the cannabinoid receptors and the endocannabinoid 
system. Since their discovery research in the field has grown 
exponentially. In which, recent developments have shown 
cannabinoids to be potent anti-inflammatory and immunosuppressive 
agents that mediate beneficial effects for many inflammatory diseases, 
including multiple sclerosis (10, 32, 33) rheumatoid arthritis, as well 
as allergy, an area of cannabinoid research in lab. Previous work done 
in our lab by Agudelo et al. 2008, showed that cannabinoids enhanced 
the IL-4/anti-CD40 mediated isotype switching from IgM to IgE in 
purified mouse B cells.  In which, CB2 was implicated as the main 
cannabinoid receptor mediating the observed enhanced increase of IgE 
in IL-4/anti-CD40 stimulated B cells.  
The gene encoding for CB2 is the CNR2 gene, however the 
regulatory elements such as the promoter, transcriptional start site 
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(TSS), and cis/trans-factors have not been described in B cells. 
Therefore, research is needed to identify these gene regulatory 
elements responsible for the expression of CB2 in B cells. The 
identification of the gene regulatory elements will lead to a better 
understanding of the pathways of CB2 expression and the mechanisms 
of increased receptor expression with changes in B cell activity. 
Identification of CB2 regulatory elements may also provide clues to 
how gene and protein expression can be therapeutically regulated in B 
cells. We propose to identify the location and sequence of the core 
promoter region(s) of the CNR2 gene in mouse and human B cells as 
well as some of the associated proximal promoter elements. Because 
CB2 is expressed highest in B cells, it is possible these cells contain 
unique features of the promoter contributing to enhanced CB2 
transcription. 
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OBJECTIVES 
 
The focus of this project is to determine the Cnr2 gene 
transcription start site (TSS) and associated promoter and cis-
sequences involved in CB2 mRNA expression in B cells as well as 
investigate transcript usage in resting and activated cells. Previous 
studies suggest a role of CB2 in the immune regulation of B cells by 
demonstrating involvement in B cell differentiation, migration, 
proliferation, and immunoglobulin class switching to IgE. A preliminary 
computational analysis of the murine Cnr2 gene and GenBank CB2 
mRNA clones revealed that two alternate transcripts containing 
different 5’UTR first exons (1 and 2) were reported. Three clones from 
immune tissues contained the exon 1 5’UTR, whereas clones 
originating from bone and liver contained the exon 2 5’UTR. This 
analysis indicated that more than one transcript is produced from the 
Cnr2 gene, and that the transcripts may be related to cell type or 
function. From this, we hypothesize that the Cnr2 gene encodes 
multiple transcripts in B cells and other immune cells, which 
14 
 
are varied following changes in cell function. In order to test this 
hypothesis, we propose the following aims: 
 
Aim 1. To Determine the Extent of CB2 Transcript Expression  
and TSSs in B cells    
Evidence in the genomic databases suggested the occurrence of 
multiple CB2 transcripts utilizing different first exons in various mouse 
tissues, as mentioned above. It is well known that the TSS is located 
either at the beginning of the first exon or upstream from it. Since 2 
first exons (exon 1 and 2) have been reported, B cells possibly express 
multiple TSSs and CB2 transcripts employing different first exons. 
Therefore, we will explore this possibility in resting B cells. To 
accomplish this aim, we will use the Switching Mechanism At 5’ end of 
RNA Transcript – Rapid Amplification of cDNA Ends (SMART 5’ RACE) 
to identify the number and location of the CB2 TSSs in splenic and 
PBMC B cells.  
 
Aim 2. To Characterize the Cnr2 Gene Promoter in B Cells  
It has been well established that accurate identification of the 
TSS leads to the location of the core promoter, which is usually -40 bp 
upstream to +40 bp downstream of the TSS. The basic elements that 
comprise the core promoter are the TATA-box, INR (Initiator), DPE 
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(downstream promoter element), and BRE (TFIIB recognition 
elements) (41). Identifying the promoter will lead to a better 
understanding of how the Cnr2 gene is regulated in B cells, which in 
turn will lead to the elucidation of the mechanisms involved in the 
immunobiology of CB2 and B cells. We will start with a bioinformatics 
analysis using web based analytical tools, such as Genomatix, to locate 
the putative promoter regions of the Cnr2 gene. These will then be 
cloned into luciferase reporter gene expression vectors and transfected 
into purified splenic B cells to test for promoter activity. Truncations of 
the clones will be performed to identify core promoter and cis-
regulatory sequences.  
 
Aim 3. To Determine CB2 Transcript Usage in Activated B cells  
as well as Other Immune Cell Subtypes  
Since CB2 is abundant in B cells and implicated in the 
involvement of various B cell functions, an understanding of transcript 
usage under varying conditions of B cell activation will be of value in 
designing future studies to regulate CB2 expression. The GenBank data 
show that multiple CB2 transcripts exists therefore, some of these 
could be unique to B cells and the various associated 5’ UTR sequences 
could provide useful targets for selectively suppressing or enhancing 
receptor expression in B cells. In this aim, we will compare CB2 
16 
 
transcript usage in resting and stimulated B cells. The literature shows 
that stimulation of B cells with anti-CD40 and/or IL-4, through STAT6 
activation, increases CB2 expression (8) (25) (1, 42), whereas, LPS 
stimulation suppresses expression (26). Therefore, to examine CB2 
transcript usage, we will stimulate purified B cells with stimuli reported 
to increase CB2 expression, such as IL4 that activates STAT6, anti-
CD40 that increases NFκB, and LPS, a known B cell mitogen, that 
binds to TLR4 and activates NFκB and/or IRF3. However, LPS has been 
shown to decrease CB2 message, therefore results from these 
experiments may uncover possible repressor elements. To perform 
these experiments, B cells will be isolated and cultured alone or with 
the various stimuli, and analyzed by RT-qPCR at various time points 
following B cell stimulation.  
Since we would like to know if any of the CB2 transcripts are 
unique in B cells, we will also analyze other immune cell subtypes, 
such as T cells, dendritic cells and macrophages for the presence of 
CB2 transcript variants.  
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MATERIALS AND METHODS 
 
Bioinformatics Analysis  
The bioinformatics programs used for this study include the 
Genetics Computer Group (GCG) SeqWeb v3.1 software package, 
Primer3, the Genomatix Suite, Consite, the Database of Transcriptional 
Start Sites (DBTSS), Ensembl and NCBI databases. 
 
Mice 
C57BL/6 mice, 8 to 10 wks old, and of mixed gender where 
obtained from NCI (Fredericksburg, MD) and housed and cared for in 
the University of South Florida Health Science Center animal facility, 
which is fully accredited by the American Association for Accreditation 
of Laboratory Animal Care. 
 
Isolation of Mouse Splenocytes, T and B cells  
Mice were euthanized by CO2 asphyxiation, followed by removal 
of the spleens, which were placed in 12 ml of Hanks balanced buffer 
saline (HBBS) then pulverized with a Seward Stomacher® 80 (Lab 
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System, England) to release the splenocytes. The splenocytes where 
collected by centrifugation at 1100 rpm for 10 minutes at 10°C, and 
washed once with PBS. The T and B cells were then isolated by 
magnetic negative selection using the EasySep® mouse T or B cell 
enrichment Kits (StemCell Technologies, Canada) following the 
manufacturer’s protocol. Total RNA was extracted from the 
lymphocytes immediately following isolation, except for B cells 
activated by LPS (5 μg/ml) for up to 8 hrs. 
 
Human Subjects, Isolation of PBMCs and B cells  
Human subjects recruited for this study were male and female 
laboratory workers at the University of South Florida, who gave 
informed consent. Venous blood (25 ml) was drawn into 4 K3 EDTA 
vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ), then diluted 
1:1 or 1:2 with RPMI 1640 medium (Sigma, St Louis, MO). The PBMCs 
were isolated from blood using Hisopaque®-1077 (Sigma Diagnostics, 
Inc.) following the manufacturer’s protocol. B cell isolation was 
performed by magnetic negative selection using the EasySep® human 
B cell enrichment kit (StemCell Technologies, Canada).  
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Phenotypic Analysis of Immune Cell Populations 
Mouse T and B cell subtypes were analyzed for enrichment by 
PCR and FACS analysis. RACE cDNA of the T and B cell samples was 
analyzed by PCR amplification using specific primers for the CD3ε chain 
of the T cell receptor and for the B cell marker CD19 (50). Enrichment 
of the B cell preparation is determined by the absence of CD3ε, while T 
cell enrichment is determined by the absence of CD19. PCR 
amplification was performed using 1 μl of RACE cDNA, 500 nM of each 
primer and Taq polymerase supplied with the SMART RACE cDNA 
Amplification kit (Clontech Inc., Madison, WI) in a final volume of  25 
μl. Amplification was for 28 cycles using the MyCycler™ thermal cycler 
(Bio-Rad Laboratories, Hercules, CA). β-actin was used as a loading 
control. FACS analysis of the purified mouse T and B cell populations 
was done by labeling 106 cells with fluorochrome-conjugated anti-
mouse mAbs; CD19-PE, CD3-PerCP, NK-pan-FITC and F/480-APC (BD 
Pharmingen, San Jose, CA). The human B cell populations were 
analyzed for enrichment by labeling 105 cells with fluorochrome-
conjugated anti-human mAbs; CD19-PE, CD3-FITC and CD14-APC (BD 
Pharmingen, San Jose, CA). All flow cytometric analysis was conducted 
using a FACS Caliber flow cytometer and Cell Quest software (Becton 
Dickinson, San Diego, CA, USA). 
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RNA Extraction 
Total RNA was extracted from the cell populations by standard 
techniques using Tri-reagent (Sigma; 1 ml per 107 cells) and 
quantitated using the RiboGreen RNA Quantitation Kit (Molecular 
Probes, Eugene, OR). Just prior to cDNA synthesis, residual DNA was 
removed by treatment with Turbo DNA-free™ (Ambion Inc., Austin, 
TX) following manufacturer’s protocol.  
 
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) 
To synthesize the cDNA, 1.0 μg of the DNAse treated RNA was 
primed with 1 μl of random primers for 5 minutes at 70°C, then 
reverse transcribed (RT) at 37°C for 1hr using 15 U avian 
myeloblastosis virus (AMV), 40 Units RNasin (Promega, Corp., 
Madison, WI ) and 1.25 mM mix of dNTPs (Promega Corp., Madison, 
WI) in a volume of 20 μl. The PCR reaction was carried out in 25 μl 
containing 1 μl cDNA, 500 nM of each primer (see Table 2), with 12.5 
μl GoTaq Green Master Mix (Promega Corp., Madison, WI) and 
amplified using the MyCycler™ thermal cycler (Bio-Rad Laboratories, 
Hercules, CA). The PCR amplification conditions were as follows; for 
the initial denaturation step, 95°C for 1 min, followed by 32 cycles at 
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95°C for 20 sec, 55°C for 30 sec, 72°C for 45 sec, with a final 
elongation at 72°C for 3 min. 
 
SMART-5’-RACE  
To identify the TSS we employed the technique; Switching 
Mechanism At 5’ end of RNA Transcript Rapid Amplification of cDNA 
Ends (SMART™ RACE cDNA Amplification kit, Clontech Inc., Madison, 
WI) following manufacturer’s protocol. Two reverse gene specific 
primers (GSP) were designed, for both mouse and human CB2 using 
the GCG SeqWeb v3.1 software (see Table 3 for primer sequences). 
The mGSP1 (mCB2-R301) binds within the ORF 301bp downstream of 
the ATG, while the hGSP1 (hCB2-R298) binds 298bp downstream of 
the ATG.  These were used with the universal primer mix (UPM) that 
anneals to the SMART sequence at the 5’ end of the cDNA supplied by 
the kit for the initial PCR reaction. A second GSP2 (mCB2-R217 and 
hCB2-R163), located 84bp upstream of mGSP1, and 74bp upstream of 
hGSP1, was used with UPM in a nested PCR for CB2 confirmation. RACE 
products were run on a 2% agarose gel, visualized with ethidium 
bromide and purified using the Perfectprep® Gel Cleanup kit 
(Eppendorf, North America) following manufacturer’s protocol, and 
sent to the Moffitt/USF Molecule Biology Core lab for DNA sequencing. 
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The SeqWeb PileUp program was used to compare the RACE 
sequences with the GenBank mCnr2 and hCNR2 sequences to confirm 
CB2 identity, exon usage, and location of the TSSs (Figures 8, 9, and 
10).  
 
 
 
Table 3. SMART 5’ RACE Primers Used to Identify the TSS. 
 
Gene Specific 
Primersa 
Sequence 5’-to-3’ 
5’ binding 
siteb 
mGSP1-R301 CGACCCCGTGGAAGACGTGGAAGATGACAA 301 bp  
mGSP2-R217 TGAACAGGTACGAGGGCTTTCT 217 bp  
hGSP1-R298 GCCAGGAAGTCAGCCCCAGCCAAGCTGCCAA 298 bp  
hGSP2-R163 GCACAGCCACGTTCTCCAGGGCACTTAGCA 163 bp  
a GSP, gene specific primer; 1 denotes for the initial RACE PCR, 2 used for 
nested PCR.  
b The number of base pairs from the start of translation in which the 5’ end 
of the GSP binds for amplification of CB2. 
 
 
 
PCR and RT-PCR Primer Mapping  
Genomic DNA was extracted from mouse splenic and human 
peripheral B cells using the Wizard® Genomic DNA Isolation System 
(Promega Corp., Madison, WI) following manufacturer’s protocol. RNA 
was extracted, DNAse treated and reverse transcribed from mouse and 
human B cells as stated above. Using Primer3, forward primers were 
designed to flank the TSSs identified by 5’RACE (Figures 11 & 12) 2 to 
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10bp in either direction. Forward primers upstream the TSS should 
only amplify genomic DNA, whereas forward primers downstream of 
the TSS should amplify genomic DNA as well as cDNA derived from the 
CB2 transcripts. The PCR reaction was carried out in 25 μl containing 
either 1 μl cDNA or 1 μl DNA, 500 nM of each primer (see Table 4), 
with 12.5 μl GoTaq Green Master Mix (Promega Corp.) and amplified 
using the MyCycler™ thermal cycler (Bio-Rad Laboratories, Inc). The 
PCR amplification conditions were as stated in section 2.6 with minor 
adjustments, the cycle number was increased to 35 and for the mouse 
samples elongation was increased to 1.5 minutes. 
 
 
 
Table 4. Primers Used for Mapping the TSSs. 
 
Primer Groupa Sequence 5’-to-3’b Assayc 
Size of 
amplicon 
mE1b     DNA   A 
   mRNA    B 
C 
G 
ggaggaggcatgaggca 
ACACATAGCCTGGCACA 
GCGGTTGAATTCTCTCTTC 
GACAAAGTTGCAGGCGAAGATCAC 
PCR 
RT-PCR 
 
189 bp 
171 bp   
 
755 bp 
mE2       DNA   D 
mRNA   E 
F 
G 
atacatcaaacacatccttg 
TTCTAGAAGGCACCCATGT 
CCTCTGCTCATTCAGGTACA 
GACAAAGTTGCAGGCGAAGATCAC 
PCR 
RT-PCR 
 
224 bp 
189 bp  
 
567 bp 
hE1        DNA    J 
    mRNA    I 
H 
gcaagagaaagctggctt 
TCAACAGGTGCTCTGAGTG 
CTGAGGAGTCCCAGTTGTT 
PCR 
RT-PCR 
99 bp 
71 bp 
a m, mouse; h, human; E1b, exon 1b; E2, exon 2; A, D, J, DNA forward 
primers; B, E, I, forward primers for amplification of mRNA derived cDNA; C, 
F, G, H, reverse primers.  
b Primers designed to bind genomic DNA 5’ of the TSSs are in lower case.   
c RT-PCR, reverse transcription polymerase chain reaction. 
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Quantitative Real Time RT-PCR (RT-qPCR) 
mCB2 transcript exonal usage in resting, LPS (5μg/ml) and IL-
4/anti-CD40 (3ng/ml, 0.5μg/ml) stimulated splenic B cells was 
measured by RT-qPCR, in which we employed a duplex Taqman PCR 
strategy; 4 mCB2 exon specific primer sets and probes were designed, 
one each for the mCB2 exons (1a, 1b, 2, and 3) and 1 primer and 
probe set for the endogenous β-actin control using Primer3 (see Table 
5 for primer/probe sequences). The real-time PCR was carried out in 
20 μl containing 1 μl cDNA, 300 nM β-actin and 500 nM CB2 primers, 
250 nM fluorescent probe (6-FAM for mCB2 exon, ROX for β-actin), 
with 10 μl IQ™ Multiplex Powermix, and performed in the iCycler IQ™ 
Real-Time PCR detection system (Bio-Rad Laboratories, Inc). In brief, 
the reaction was performed in duplicate for each RT cDNA product (see 
above). Samples were heated for 10 min at 95 °C, followed by 50 
cycles of amplification for 15 s at 95 °C and 1 min at 60 °C.  
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Table 5. Primers and Taqman® Probes Used in This Study. 
 
Primer pairsa 
and probe 
Sequence 5’-to-3’b 
Size of 
amplicon 
mCB2-E3      F 
R 
P 
GCCGTGCTCTATATTATCCTGTCCTC 
GACAAAGTTGCAGGCGAAGATCAC 
6FAM-AGAAAGCCCTCGTACCTGTTCATCAGCA-BHQ1 
120 bp 
mCB2-E1a    F 
R 
P  
TCATCTGCGAAAGTGTGA 
TTGTCCTGGCTATTCTGTATC 
6FAM-CTGGAGCTGCAGCTCTTGGGAC-BHQ1 
112 bp 
mCB2-E1b    F 
R 
P 
ACACATAGCCTGGCACA 
GCGGTTGAATTCTCTCTTC 
6FAM-TCAAGTGAGTTGCAGGACAGCATAC-BHQ1 
171 bp 
mCB2-E2      F 
R 
P 
TTCTAGAAGGCACCCATGT 
CCTCTGCTCATTCAGGTACA 
6FAM-CTTCCTGTTGCTGTGTGCATCCT-BHQ1 
189 bp 
β-actin         F  
R 
P 
GGGAATGGGTCAGAAGGACT 
AGGTGTGGTGCCAGATCTTC 
ROX-ATGTGGGTGACGAGGCCCAGAGCAA-BHQ2 
134 bp 
a E3, exon 3; E1a, exon 1a; E1b, exon 1b; E2, exon 2; F, forward primer; R, 
reverse primer; P, Taqman® probe.  
b 6FAM, 6-carboxyfluorescein; BHQ1 or 2, Black Hole Quencher®-1 or 2.  
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Promoter Cloning 
 Using genomic DNA extracted from B cells (see above) and the 
pGL3-enhancer vector (Promega), clones were constructed to test for 
promoter activity surrounding the TSSs of the mouse exon 1 and 2 CB2 
transcript variants. The clones included the region from -359 bp to 
+205 bp of the TSS (+1) of exon 1a, whereas the exon 2 clones 
spanned the region from -189 bp to +205 bp of the exon 2 TSS (+1). 
The DNA regions were PCR amplified (see table 6 for primer 
sequences) and initially cloned into the pTOPO-Blue TA vector 
(Invitrogen) following manufacturer’s protocol, then sub-cloned by 
standard methods, into the pGL3-enhancer vector via the Hind III 
restriction enzyme site. 
 
Table 6. Promoter Clones and PCR Primers.  
Promoter 
clone 
Primers Sequence 5’-to-3’ 
Promoter region 
cloned 
Size 
(bp) 
pGL3-E16 E1-352F 
E1+123R 
GGCACATGTCACAGACAA 
GCGAAGAGTTAGGGAAGAGT 
-270 bp to +205 bp 
exon 1a TSS(+1) 
475  
pGL3-E19 E1-14F 
E1+123R 
CCTGCTGGGTCTCCAGAT 
GCGAAGAGTTAGGGAAGAGT 
+68 bp to +205 bp 
exon 1a TSS(+1) 
137 
pGL3-E25 E1-441F 
E1-19R 
GTTCAATTCCCAGCACCC 
CCCACGTAGGTCCCAAGAG 
-359 bp to +63 bp 
exon 1a TSS(+1) 
422 
pGL3-P7 E2-F189 
E2+R36 
CTTGCCAGTTCCCAGTTTCA 
CAAGTCACATGGGTGCCTTCT 
-189 bp to +36 bp 
exon 2 TSS(+1) 
225 
pGL3-P8 E2-F90 
E2+R36 
AGAAGAGGGACTTGCCCAAA 
CAAGTCACATGGGTGCCTTCT  
-90 bp to +36 bp 
exon 2 TSS(+1) 
126 
pGL3-P10 E2+F13 
E2+R205 
TCTAGAAGGCACCCATGTGA 
CTGTGCCTCTGCTCATTCAG 
+13 bp to +205 bp 
exon 2 TSS(+1) 
192 
pGL3-P11 E2-F189 
E2+R101 
CTTGCCAGTTCCCAGTTTCA 
AACAGGATGCACACAGCAAC 
-189 bp to +101 bp 
exon 2 TSS(+1) 
290 
pGL3-P13 E2-F25 
E2+R101 
TCAAACACATCCTTGCCCTA 
AACAGGATGCACACAGCAAC 
-25 bp to +101 bp 
exon 2 TSS(+1) 
126 
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Transfection of B cells 
 Primary B cells were cultured for 24 to 48 hrs in RPMI medium 
containing 10% FCS, 10 ng/ml IL-4 and 500 ng/ml anti-CD40, then 
transfected (107cells/500μl RPMI in 0.4-cm cuvettes) with the pGL3-
clones (10μg) by electroporation at 250 V and 800 μFarads using the 
Gene Pulser (BioRad). The transfected B cells were collected within 18 
to 24 hrs after electroporation. For each cell sample a 50 μl aliquot 
was removed and mixed with an equal volume of Trypan Blue to 
obtain cell number and check viability. Cells were counted using a 
hemocytometer and compound light microscope. 
 
Luciferase Reporter Assay 
 Cell lysates of the transfected cells were analyzed for luciferase 
activity using Promega’s Luciferase Assay System, following 
manufacturer’s protocol. In brief, cells were collected by centrifugation 
at 600 RCF for 10 minutes and washed 1X with PBS. Cells were lysed 
using 200 μl of CCLR, of which 20 μl was used for the luciferase assay 
and the remaining lysate was stored at -80˚C. Each sample was in 
duplicate and luciferase activity was measured using the MLX 
luminometer (Dynex Technologies Inc., Chantilly, VA). A standard 
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curve was used to measure the amount of lucerifase protein in each 
sample. 
 
Activation of B Cells 
To activate B cells we used the B cell mitogen, LPS, and known 
inducers of immunoglobulin class switching IL-4 and anti-CD40. 
Purified primary splenic B cells were cultured in RPMI medium 
containing 10% FCS with either 5 μg/ml LPS or 3 ng/ml IL-4 and 0.5 
μg/ml anti-CD40 for 1, 3, and 8 hrs. Total RNA was isolated at each 
time point and analyzed for transcript expression by RT-qPCR. Relative 
transcript expression was determined by the 2-ΔΔCt method, in which β-
actin was the endogenous control and time 0 (un-stimulated) was the 
calibrator.   
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RESULTS 
 
Aim 1. To Determine the Extent of CB2 Transcript Expression  
and TSSs in B cells. 
 
Bioinformatics Analysis of the CB2 Gene (Cnr2) and GenBank™  
Clones. 
 Since the discovery of CB2, several cDNA clones from various 
mouse and human tissues, as well as the complete gene sequence 
have been submitted to GenBank and available to researchers. We 
therefore took advantage of this resource to gain initial insight as to 
how the CB2 receptor gene is expressed in B cells. Initially we explored 
genome databases, such as Ensembl and NCBI, to obtain the location 
and gene structure of mouse and human CNR2. The mouse Cnr2 
(mCnr2) was reported to be located on chromosome 4, 24.7 kb in size, 
and produce at least two transcripts containing different 5’ 
untranslated region (UTR) first exons (Figure 3A & 3B). Whereas 
human CNR2 (hCNR2) was reported on chromosome 1, 39.4 kb in 
size, and express a single transcript (Figure 4A & 4B). A consensus 
was reported among the mouse and human clones in which the ORF, 
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encoding CB2 protein, was within a single exon -- exon 3 for mouse 
and exon 2 for human (Figures 3 and 4). Further computational 
analysis using the GCG SeqWeb package to align the 5’UTR of the 
GenBank™ clones, revealed the mouse clones from various immune 
tissues share a similar 5’UTR first exon (exon 1) that differed in length 
at their most 5’ nucleotide. Similarly, the clones reported from bone 
and liver share a second common 5’UTR first exon (exon 2) yet differ 
in length at the 5’ nucleotide (Figure 3C). Analysis of human data 
(Figure 4C) showed only one full length human CB2 clone containing a 
5’UTR first exon (exon 1). This analysis suggested that mCnr2 utilizes 
multiple TSSs to produce at least two CB2 transcript variants whereas 
the human gene utilizes only one. However, none of this existing data 
provided information as to the location of the TSS and CB2 transcript 
variants utilized in B cells. Therefore, we began to investigate the TSS 
and CB2 transcripts in B cells purified from mouse splenocytes and 
human PBMCs. 
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Figure 3. Computational Analysis of the Mouse Cnr2 Gene.  
A. Chromosome location of the mCnr2 (GenBank accession no. NC000070). 
B. The mCnr2 gene structure. Boxes represent exons, whereas white boxes 
are the untranslated region (UTR) and the dark grey shaded area is the 
protein coding region. ORF = open reading frame. Dotted lines are introns, 
which are spliced out to form mature mRNA. C. GenBank CB2 mRNA 
transcripts; mCB2 exon 1 transcripts are expressed in the murine leukemic 
cell line NFS107 (GenBank accession nos. X93168, NM009924), the spleen 
and thymus (GenBank accession nos. X86405, and AK037898), whereas 
mCB2 exon 2 transcripts are expressed in liver and bone (GenBank accession 
nos. BC024052 and AK036658). 
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Figure 4. Computational Analysis of the Human CNR2 Gene.  
A. Chromosome location of the hCNR2 (GenBank accession no. NC000001). 
B. The hCNR2 gene structure. Boxes represent exons, whereas white boxes 
are the untranslated region (UTR) and the dark grey shaded area is the 
protein coding region. ORF = open reading frame. Dotted lines are introns, 
which are spliced out to form mature mRNA. C. GenBank hCB2 mRNA 
transcripts are expressed in the human promyelocytic leukemic cell line 
HL60, human embryonic kidney cell line HEK293, brain, and leukocytes 
(GenBank accession nos. NM001841, AV430063, BC074767, and AM156854-
6). 
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Phenotype of Lymphocyte Subtypes 
Studies have shown that CB2 mRNA is most abundant in mouse 
and human B cells (8, 16, 25) and the bioinformatic analysis 
performed above revealed that the mCnr2 produces at least two 
transcripts, whereas the hCNR2 produces only one (Figures 5 and 6). 
However, from the database we could not find any information 
pertaining to the location of the TSS or CB2 transcript usage in purified 
mouse and human B cells. Therefore, we began an analysis for CB2 
transcript initiation and usage in un-stimulated, resting purified B cells 
from mouse splenocytes and human PBMCs. T and B cells were 
purified using the EasySep® negative selection kits for mouse and 
human. Splenocytes from mice and blood mononuclear cells from 
humans were processed over antibody affinity columns to remove all 
lymphoid subtypes with the exception of B cells and T cells.  We then 
employed RT-PCR and flow cytometry to determine enrichment of the 
lymphocyte subtypes. RT-PCR determined either the presence or 
absence of the T cell specific CD3ε message or the B cell specific 
message, CD19. Enrichment of the B cell preparation was determined 
by the presence of CD19 and absence of CD3ε, whereas T cell 
enrichment was determined by the presence of CD3ε and absence of 
CD19. PCR amplification was performed using CD3ε and CD19 specific 
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primers (50) for 28 cycles, in which weak to no visible CD19 bands 
were seen in the T cell populations and weak CD3ε bands were seen in 
the B cell population (Figure 5A). Because of the weak bands seen in 
the lymphocyte subtypes, we were unable to determine the percent 
purification of the lymphocyte subtypes. Therefore, to determine more 
precisely the purity of the subtypes, we performed flow cytometry 
analysis using CD19 and CD3 fluorescent labeled antibodies and 
demonstrated that the mouse B and T cell populations as well as the 
human B cell populations were enriched to greater than 95% (Figures 
5 and 6). These results show that the purified lymphocyte subtypes 
were indeed highly enriched. 
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Figure 5. Phenotypic Analysis of Mouse Immune Cell Subtypes.  
Mouse B and T cells isolated from splenocytes by affinity purification 
(EasySep®) A. RT-PCR for the presence of the CD3ε message in T cells and 
for B cell specific marker CD19; β-actin used as loading control. B. Flow 
cytometry analysis of lymphocytes treated with CD19-PE, CD3-PerCP, NK-
pan-FITC and F/480-APC anti-mouse mAbs (FITC and APC data not shown) 
to determine lymphocyte enrichment. C. Graph represents data of 5 
independent B cell purification procedures (black bar). Grey bars are CD3+ 
cells. 
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Figure 6. Phenotypic Analysis of Lymphocyte Subtypes Isolated from 
Human PBMCs. 
A. Human B cells isolated from PBMCs by affinity purification were analyzed 
with CD19-PE, CD3-FITC and CD14-APC anti-human mAbs (CD14 data not 
shown) to determine B cell enrichment. B. Graph represents data from 3 
human donors. Black bars are B cells and grey bars are T cells. 
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Mouse and Human B cells Differ in the Number of CB2 TSSs. 
 To determine the location of the mCnr2 TSS in purified B cells, 
we employed the SMART 5’ RACE technique. Figure 7 shows RACE 
results of RNA isolated from mouse and human B cells. For mouse 
cells, we used the GSP1, mCB2-R301, along with the UPM primer 
supplied with the kit. RACE PCR yielded three mCB2 transcripts that 
were confirmed as CB2 RACE products by nested PCR (Figure 7A). 
RACE was also performed on human B cell RNA using the hCB2-R298 
GSP1 with the UPM, followed by nested PCR using hCB2-R163 GSP2, 
resulting in the demonstration of only one transcript (Figure 7B). In 
order to determine the relative gene location of the TSSs and 5’UTR 
structure of the CB2 transcripts in B cells, the RACE products were 
isolated, sequenced and the nucleotides aligned for analysis. The 
location of the TSS was revealed by alignment of the 5’ end of the 
RACE sequences with the UPM- SII oligo primer sequence and genomic 
DNA (Figure 8). Furthermore, alignment of the sequenced RACE 
products to either the mouse or human genome, along with the 
GenBank submitted mRNA sequences revealed several new aspects of 
CB2 transcript expression in B cells. First the mouse transcripts were 
homologous to the Cnr2 as well as the existing CB2 mRNA data, with 
the exception that exons 1 and 2 in the transcripts we isolated were 
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longer by 14 to 294 nucleotides, respectively, indicating they 
contained previously unidentified TSSs. Mouse B cells also expressed 
and additional transcript, exon 1b, with three TSSs (Figure 9).  
Regarding transcript usage in human B cells, data obtained from three 
human subjects showed expression of only one first exon (Figure 10). 
To our knowledge, this is the first report identifying TSSs in B cells 
from mouse and human and these sequences have been submitted to 
GenBank (accession nos. FJ357033-6). 
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Figure 7. CB2 Transcripts and TSSs Identified by 5’ RACE.  
Gel electrophoresis of the 5’ RACE products visualized on a 2% agarose gel 
stained with ethidium bromide. primary PCR (1°), nested PCR (2°). A. Mouse 
5’ RACE products, 1° product length; exon 1b, 778-788 bp; exon 2, 614 bp; 
exon 1a, 543 bp. 2° size; exon 1b, 697-707 bp; exon 2, 533 bp; exon 1a, 
459 bp B. Human 5’ RACE product, 1°, 455 bp; 2°, 381 bp.  
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Mouse exon 1a RACE products 
                                   +1 
Cnr2        CACCAGACCTCCTCTCATTCACTCATCTGCGAAAGTGTGAGAGCAAG 
Spleen AACGCAGAGTACGCGGGGATCTGCGAAAGTGTGAGAGCAAG 
Spleen AACGCAGAGTACGCGGTGATCTGCGAAAGTGTGAGAGCAAG 
B cell AACGCAGAGTACGCGGGGATCTGCGAAAGTGTGAGAGCAAG 
B cell AACGCAGAGTACGCGGTGATCTGCGAAAGTGTGAGAGCAAG 
B cell AAGGCAGAGTAGGGGGTCATCTGCGAAAGTGTGAGAGCAAG 
B cell AACGCAGAGTACGCGGGGATCTGCGAAAGTGTGAGAGCAAG 
B cell ATCTGCGAAAGTGTGAGAGCAAG 
 
 
Mouse exon 1b RACE products 
                       +1          +1     +1 
Cnr2 AGGCATGAGGCACACACATAGCCTGGCACATGTCACAGACAAAAGGATGT 
Spleen AACGCAGAGTACGACGGGACAGACAGAAGGATGT 
B cell ACGCAGAGTACGCGGGGACAGACAAAAGGATGT 
B cell CGCAGAGTACGCGGGGACAGACAAAAGGATGT 
B cell ACGCAGAGTACGCGGGGACATGTCACAGACAAAAGGATGT 
B cell CAAGCAGGGGTATACATACCGTGTCACATGTCACAGACAAAAGGATGT 
B cell TACATAGCCTGGCACATGTCACAGACAAAAGGATGT 
B cell ACAGCATGGGTATACATAGCGTGGCACAGGTCACAGACAAAAGGATGT 
 
      
Mouse exon 2 RACE products 
       +1 
Cnr2 TATACATCAAACACATCCTTGCCCTAGAAATAGGTCTTCTAGAAGGCA 
Spleen AAGCAGAGTACGCGGGGAGAAATAGGTCTTCTAGAAGGCA 
Spleen GGGGGAGAAATAGGTCTTCTAGAAGGCA 
B cell AAGCCGAGTTCGGCGGGAGAAATAGGTCTTCTAGAAGGCA 
B cell ACGCAGAGTACGGCGGGAGAAATAGGTCTTCTAGAAGGCA 
B cell GGGGAGAAATAGGTCTTCTAGAAGGCA 
 
Human RACE products 
                                  +1 
CNR2       AGCAAGAGAAAGCTGGCTTGGGGTGGCACTCAACAGGTGCTCTGAGTG 
B cell                    TACGCGGGGGGCACTCAACAGGTGCTCTGAGTG 
B cell                        CGGGGGGCACTCAACAGGTGCTCTGAGTG 
B cell              ACGCAGAGTCGCGGGGGCACTCAACAGGTGCTCTGAGTG 
 
 
Figure 8. 5’ RACE Products Reveal Location of the TSSs. To determine 
the TSS, the GCG SeqWeb PileUp program was used to align the 5’ end of 
the RACE products with the CNR2 gene and the UPM (AACGCAGAGT)-SII Oligo 
(ACGCGGG) sequences supplied with the RACE kit. TSSs are bold underlined 
and marked as +1. Shaded grey indicates the kit primers.  
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exon 1 exon 2 exon 3
exon 1b,  652-62bp
exon 1a,  414bp 
exon 2,    488bp
ORF
-14
-294,-282,-275
5’ 3’
Exon 1a: 151 bp
ATCTGCGAAAGTGTGAGAGCAAGAAACCCCAGGCTGGAGCTGCAGCTCTTGGGACCTACG
TGGGGGTCCCTGCTGGGTCTCCAGATCTGGATACAGAATAGCCAGGACAAGGCTCCACAA
GACCCTGGGGCCCAGCGGCTGACAAATGACA
-14
Exon 1b: 412, 419, & 431 bp
ACATAGCGTGGCACATGTCACAGACAAAAGGATGTAAACTTTACAGAGGTCAAGTGAGTT
GCAGGACAGCATACACCCGGGGCCAGATTAGAACCCAAGTTTCTGGAGTCTAAGGTCTAT
GCCTATGCCCTCCCCTGGCCAGAGTTCCTAGGAAGAGAGAATTCAACCGCAGGGCAAGAA
CACTGTGGCACTGAGGACCCAGAGGGGAAGTGGTAACCGGTACGGAAGGCCAGATCTCCT
CTCACTCACTTATCTGCACCAGACCTCCTCTCATTCACTCATTTGCGAAAGTGTGAGAGC
AAGAAACCCCAGGCTGGAGCTGCAGCTCTTGGGACCTACGTGGGGGTCCCTGCTGGGTCT
CCAGATCTGGATACAGAATAGCCAGGACAAGGCTCCACAAGACCCTGGGGCCCAGCGGCT
GACAAATGACA
-294 -275-282
Exon 2: 253 bp
AGAAATAGGTCTTCTAGAAGGCACCCATGTGACTTGCAGAGGGTATCTCTATCTTCGTGG
AGACAGGGAGCCGGGCTTCCTGTTGCTGTGTGCATCCTGTTGTTCTCTTGTTAGGATGTC
CATCAAATGCATGCATTTCCTTTCCTAACTCTGGACAGTAACAGTCGTCTGCGGCCAAGC
TGTGCCTGAATGAGCAGAGGCACAGGCACCAGCCGTGGCCACCCAGCAAACATCTCTGCT
GACTCAGACTGGG
-172
 
 
 
Figure 9. The Cnr2 Gene Location of the TSSs and 5’UTR Sequences 
Identified by 5’ RACE. CB2 transcripts are labeled with their corresponding 
exon along with the number of nucleotides sequenced for each RACE product. 
The upward arrows represent the Cnr2 gene location of the TSSs (underlined 
nucleotide) relative to position 1 (bold underlined nucleotide) of the 
Genbank™ accession nos. NM009924 for exons 1a & 1b and BC024052 for 
exon 2. Small black arrows mark the relative location of the GSPs. The 5’UTR 
exon sequences of the mCB2 transcripts submitted to GenBank (accession 
nos. FJ357033-5). 
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Exon 1: 117 bp
GGGTGTGTTGTGGGTGGCTGGGCACTGGGAGCTGCCGGGGGGTGAGGAGTCCC
AGTTGTTTTTTGTCCTCTCCCAGGACCTGGCCGTGGGTGCCACTCAGAGCACC
TGTTGAGTGCC
-35
exon 1, 410bp
ORF
exon 2 exon 1
-35
3’ 5’
 
 
 
 
 
Figure 10. Human CB2 5’RACE Transcripts have a Single TSS and 
5’UTR. The CNR2 gene location of the TSS (upward arrow). Number below 
the arrow represents the location of the TSS (underlined nucleotide) relative 
to position 1 (bold underlined nucleotide) of Genbank™ accession no. 
NM001841. Small black arrows mark the relative location of the GSPs. The 
CB2 5’UTR exon 1 sequence submitted to GenBank (accession no. FJ357036).  
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To verify the relative location of the TSSs, we designed specific 
forward primers for PCR of either genomic DNA or cDNA reverse 
transcribed from 1 μg of total RNA. The strategy for these experiments 
is illustrated in figures 11A and 12A. In brief, the forward primers were 
designed so that either the 3’ or 5’ end borders the TSS. 
Consequently, the forward primer in which the 3’ end is adjacent to 
the TSS will only amplify genomic DNA and not the cDNA derived from 
the mRNA transcripts, whereas the forward primer that adjoins the 
TSS at the 5’ end will amplify both genomic DNA and cDNA. There is 
some limitation with this approach in that it is not as sensitive as 5’ 
RACE in determining the TSS, but it does help confirm the relative 
location of the TSS and approximate 5’ end of the transcripts. 
Therefore, using this approach we were able to confirm the TSS 
location of mCB2 exons 1b and 2 (Figure 11B), as well as the hCB2 
exon 1 transcript (Figure 12B). Another limitation with the assay was 
that mouse exons 1a and 1b share identical sequences with the 
exception that exon 1b is 280 nucleotides longer at the 5’ end. 
Consequently, primers designed to adjoin the TSS of exon 1a would 
not be able to distinguish genomic DNA from cDNA derived from exon 
1b and would amplify both. Therefore, we could not use this approach 
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to verify the location of the TSS for transcripts containing exon 1a in B 
cells. 
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Figure 11. Primer Mapping of the mCB2 TSSs. A. Illustration of the 
strategy for primer mapping of the mCB2 TSSs. Forward primers A and D 
(black arrows) only amplify genomic DNA while forward primers B and E 
(grey arrows) amplify both genomic DNA and cDNA derived from CB2 mRNA. 
The reverse primers C, F, and G (grey arrows) are shown. The blown out 
sequences illustrate where the forward primers bind in relation to the TSSs. 
The bold letters are the 3’ and 5’ end of the forward primers, and underlined 
nucleotides are the TSS B. Gel electrophoresis of the mapped CB2 transcripts, 
where in lane 1 contains cDNA derived from 1 μg of total RNA from mouse 
splenic B cells, lane 2 is genomic DNA extracted from B cells, and lane 3 
contains the no template control. The bands are labeled with the primer pair 
(white letters) used for PCR amplification. The panels are labeled with the 
exon TSS tested. 
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Figure 12. Primer Mapping of hCB2 TSS. A. Forward primer J (black 
arrow) only amplifies genomic DNA and forward primer I (grey arrow) 
amplifies both genomic DNA and the cDNA derived from CB2 mRNA. The 
reverse primer H (grey arrow) is shown. The blown out sequence illustrates 
where the forward primers bind in relation to the TSSs. The bold letters are 
the 3’ and 5’ end of the forward primers, and the underlined nucleotide is the 
TSS. B. Gel electrophoresis of the mapped hCB2 transcript, where in lane 1 
contains cDNA derived from 1 μg of total RNA from human PBMC B cells, lane 
2 is genomic DNA extracted from B cells, and lane 3 contains the no template 
control. The primers used for each PCR are labeled in white above the bands. 
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Preferential Usage of the CB2 Exon 1a Transcript Variant in  
Resting Splenic B Cells  
The 5’ RACE data revealed that resting splenic B cells expressed 
several CB2 transcripts. Therefore, in order to determine which 
transcript was most abundant we used RT-PCR to quantify the 
transcripts. Using exon specific primers, semi-quantitative RT-PCR 
showed exon 3-containing transcripts and those containing variants of 
exon 1 rather than exon 2 predominated in resting B cells (Figure 
13A). To better define these results we used quantitative real time RT-
PCR (RT-qPCR). The primers and CB2 exon specific taqman sequences, 
listed in table 5 and located as black boxes in the diagram of figure 13, 
were used in conjunction with β-actin primers and taqman probe in a 
duplex RT-qPCR. Since all three transcripts include exon 3, primers 
designed for this exon will amplify all the transcripts regardless of the 
first exon. In addition primers designed for exon 1a should amplify all 
transcripts containing exon 1, whereas primers for exon 1b and 2 were 
designed to specifically amplify transcripts containing only these 
exons. Our results show that the exon 1a transcript variant was the 
most abundantly expressed transcript in un-stimulated resting splenic 
B cells (Figure 13B). 
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Figure 13. Quantitative real time RT-PCR (RT-qPCR) for mCB2 mRNA 
Expression in Resting Splenic B cells.  A. Semi-quantitative RT-PCR of 
the mCB2 transcripts using exon specific primers and 2 separate mouse B cell 
samples. The samples were collected after 32 cycles of amplification and run 
on a 2% agarose gel visualized with ethidium bromide. B. Using taqman 
probes; RT-qPCR was performed to determine the major CB2 transcript 
utilized in mouse B cells at basal transcription. Results were normalized with 
β-actin and expressed as a ratio of CB2 transcript/β-actin. Data are means ± 
S.E.M. of five independent experiments.  
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Aim 2. Characterize the Cnr2 Promoter in B Cells 
 
Bioinformatics Analysis for Core Promoter Elements Near the  
TSSs  
 It has been well established that identification of the TSS will 
lead to the location of the core promoter, which is usually -40 bp 
upstream to +40 bp downstream of the TSS. The basic elements that 
comprise the core promoter are the TATA-box, INR (Initiator), DPE 
(downstream promoter element), and BRE (TFIIB recognition 
elements) (41). Therefore, we performed a bioinformatics analysis for 
the presence of consensus sequence of the core promoter elements in 
the vicinity of our RACE TSSs to tentatively identify the structure and 
location of the Cnr2 core promoter. Using GCG SeqWeb, we aligned 
the 5’ ends of the RACE sequences with that of previously described 
CB2 mRNA sequences (GenBank accession nos. NM009924 for mouse, 
and NM001841 for human) as well as the Cnr2 genomic region 
spanning -45 bp to +50 bp of the RACE TSSs (positions +1, Figure 
13), followed by in silico analysis for core element consensus 
sequences. For exon 1a, we identified an INR sequence spanning the 
area -2 bp to +5 bp surrounding the TSS (+1), a TATA-like sequence 
at position -25 bp as well as multiple DPEs and DCEs at positions 
+10,18,31,36,38, and +44 bp. The RACE results for the exon 1b 
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transcript identified 3 TSSs, which from this analysis appear to have 
INR-like sequences. In addition, a GC/GAGA-box spanning 24 bp is 
present that is -24, -25, -26 bp as well as multiple DPE sites at 
+30,33,29, and +35 bp from its respective TSS. The exon 2 RACE 
transcript has an INR-like sequence, a TATA-box at -21 bp as well as 
DCE at +11 bp and a DPE at +25 bp (Figure 14A). The RACE 
transcripts from human also contain an INR-like sequence, as well as a 
TATA-box at -31 bp, a BREd -24 bp and a DPE at +35 bp (Figure 14B). 
From this analysis it appears that the consensus sequences for core 
promoter elements are in the vicinity of the TSSs identified by the 5’ 
RACE experiments. Furthermore, the analysis suggested that mCnr2 
has three potential core promoters for the pre-initiation complex to 
assemble for transcription initiation, whereas hCNR2 has a single 
putative core promoter.
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5’          GC-box and GAGA-box  INR INR INR DPE            DPE DPE 3’
exon 1b (n=3)                                            ACAGACAAAAGGATGTAAACTTTACAGAGGTCAAGTGAGT
exon 1b (n=1)                                           ACATGTCACAGACAAAAGGATGTAAACTTTACAGAGGTCAAGTGAGT
exon 1b (n=3)                                  ACATAGCCTGGCACATGTCACAGACAAAAGGATGTAAACTTTACAGAGGTCAAGTGAGT
DNA     CTCAAAGCTCTGGGCGAGAGGGAGGAGGCATGAGGCACACACATAGCCTGGCACATGTCACAGACAAAAGGATGTAAACTTTACAGAGGTCAAGTGAGT
-40 -25 -26     -24   +1 +1     +1 +30 +33+29 +35 +40
5’ TATA-box                      INR DPE DCE     DPE  DCE/DPE DCE   3’
NM_009924     gagagcaagaaaccccaggctggagctgcagctctt
exon 1a (n=11)                                           ATCTGCGAAAGTGTGAGAGCAAGAAACCCCAGGCTGGAGCTGCAGCTCTT
exon 1a (n=4)                                          TCATCTGCGAAAGTGTGAGAGCAAGAAACCCCAGGCTGGAGCTGCAGCTCTT
DNA TCCTCTCACTTATCTGCACCAGACCTCCTCTCATTCACTCATCTGCGAAAGTGTGAGAGCAAGAAACCCCAGGCTGGAGCTGCAGCTCTT
-40           -25             +1 +10     +18          +31  +36/38  +44   +50
A.
5’  TATA-box                     INR DCE           DPE            3’
exon 2 (n=5)              AGAAATAGGTCTTCTAGAAGGCACCCATGTGACTTGCAGA
DNA          CCCAGAGCAGCTACTTATACATCAAACACATCCTTGCCCTAGAAATAGGTCTTCTAGAAGGCACCCATGTGACTTGCAGA
-40                -21         +1     +11           +25            +40
              
 
 
 
B. 3’ DPE                                INR BREd TATA-box  5’NM_001841    gacctg
exon 1 (n=3) GACCTGGCCGTGGGTGCCACTCAGAGCACCTGTTGAGTGCC
DNA                       GACCTGGCCGTGGGTGCCACTCAGAGCACCTGTTGAGTGCCACCCCAAGCCAGCTTTCTCTTGCTTTTGTACTTTCTCACA
+40  +35                                +1    -24    -31      -40
 
 
Figure 14. Putative Core Promoter Elements Near the TSSs. The gene region spanning approximately -40 bp 
to +40 bp of the TSSs was analyzed for core promoter elements. A. The putative core promoters of the three mCB2 
transcripts. For exon 1b the numbers for the TSSs (+1) are color coordinated with their respective core promoter 
element. B. The hCNR2 gene putative core promoter. INR, Initiator (consensus sequence YYANWYY). DPE, 
Downstream promoter element (consensus sequence RGWCGTG) BREd, TFIIB recognition element downstream the 
TATA-box (consensus sequence RTDKKKK). 
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Bioinformatics Analysis to Identify Putative Promoters and cis- 
Sequences 
 It is well accepted that the promoter consists of two interacting 
components; the core promoter, in which the basic transcription 
factors join with Pol II at the TSS to form the pre-initiation complex 
and the regulatory elements that are involved in activated 
transcription (51). These regulatory elements consist of proximal 
elements, next to the core promoter, and enhancers/repressors 
elements, which can be located several kbs upstream or downstream 
the TSS. These regulatory elements, known as cis-sequences are the 
DNA binding sites for transcription factors. Identifying the Cnr2 
promoter and cis-sequences will provide insight into how this gene is 
regulated in B cells during different states of activation.  
 Bioinformatics has become a useful tool in identifying sequences 
that may be involved in regulating gene transcription that can then be 
experimentally tested. Therefore, to increase our understanding of the 
functional regulatory regions that control CB2 transcription we utilized 
several web-base programs to tentatively locate the Cnr2 promoter 
and cis-sequences. Functional regulatory regions tend to be close to 
the TSS, therefore our first analysis was to locate putative promoters 
near our 5’ RACE TSSs. To accomplish this we used the Genomatix 
suite to analyze 1 kb of the Cnr2 genomic sequence (obtain from 
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GenBank) surrounding the TSSs for exons 1 and 2. The analysis 
yielded two predicted promoter regions for the mCnr2 and one for the 
hCNR2. The first mCnr2 predicted promoter is 690 bp and spans the 
region -574 bp to +115 bp from the mCB2 exon 1a TSS (+1). The 
second mCnr2 promoter is 601 bp and spans -362 bp to +238 bp from 
the mCB2 exon 2 TSS (+1). The single hCNR2 predicted promoter is 
601 bp spanning -406 bp to +135 bp of the TSS (+1).  
 To identify putative cis-sequences, we used the same 1 kb 
genomic regions as above and the MatInspector program of the 
Genomatix suite, which this analysis yielded numerous cis-sequences 
that hampered us to decipher the true positives from the false. 
Therefore, we used the process of phylogenetic footprinting, in which 
ClustalW was used to align the entire Cnr2 gene of mouse and human 
to find conserved regulatory regions. Alignment of the orthologous 
genes paralleled the Genomatix promoter prediction for the exon 1 
region (Figure 15A). In addition, the orthologous alignment of the 
genomic region near the mouse exon 2 showed high conservation 
between mouse and human suggesting the possibility of an exon 2 for 
human CNR2, which the Genomatix analysis did not reveal (Figure 
15B). Exon 1 and 2 regions were further analyzed using the Consite 
web-base program for conserved cis-sequence regions. The exon 1 
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alignment revealed conserved cis-sequences for Elk-1 and c-REL, as 
well as DNA binding sites for STAT6 and NF-kBp50 for mouse, GATA 
and STAT for human. Similar results were obtained for the exon 2 
alignment indicating a conserved NF-kB, p65, c-REL cis-sequence and 
single STAT6 DNA binding sites for both mouse and human (Figure 
15). The results obtained from these analyses exemplified the 
usefulness of employing bioinformatics as a tool to direct research in 
locating candidate Cnr2 gene regulatory regions that can then be 
experimentally tested for functionality, as well as guide future research 
in understanding the interplay between the cis-sequences and trans-
factors that regulate Cnr2 in B cells. 
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A. Exon 1 alignment 
 Mus_musculus  CAGGAGCCAGCAGCGTTCATTCATGTCATCTGCCAACACCTGCAGGCATTTGCATCTCAA 
 Homo_sapiens  CAGGATCCATCACC---CATTATGTTAATCTGCC------TGTAGGCATTTGCATTTCAA 
                                                     +1 
 Mus_musculus  AGCTCTGGGCGAGAGG-GAGGAGGCATGAGGCACACACAT-------------------- 
 Homo_sapiens  AGCTCTGGCCTAGTGGTGAAGAGGCATTGGAATGGCATGTCCTTTTAGGTGATCTACTGT 
                                   +1     +1  GATA            STAT 
 Mus_musculus  -AGCCTGG---------CACATGTCACAGACAAAAGGATGTAAACTTTACAGAGGTCAAG 
 Homo_sapiens  AATGTTGGTGCATTATCCCCATTTTACAGATAAAGAAACTTGC-CTTTGGGGAAGTTAAG 
 
 Mus_musculus  TGAGTTGCAGGACAGCATACACCCGGGGCCAGATTAGAACCCAAGTTTCTGGAGTCTAAG 
 Homo_sapiens  TGAAT-------CAACATTTTAACGAGGCTGTATTAGAACCCAAGTCCCTTGACTCCAGG 
                                                 STAT6      GATA 
 Mus_musculus  GTCTATGCCTATGCCCTCCCCTGGCCAGAGTTCCTAGGAAGAGAGAATTCAACCGCAGGG 
 Homo_sapiens  GTCTAGGCCCATGCCCCACCCTGGCCAGAGTTCGTTGTAAGAGATAACTCAACCGCAGGG 
         Elk-1,  c-REL 
 Mus_musculus  -CAAGAACACTGTGGCACTGAGGACCCAGAGGGGAAGTGGTAACCGGTACGGAAGGCCAG 
 Homo_sapiens  GCAAGAGCATTGTGGCACCAGGGACCTGGAGGGGAAGTGGTAACAGGCACGGAAGGCCAG 
                             GATA                                +1 
 Mus_musculus  ATCTCCTCTCACTCACTTATCTGCACCAGACCTCCTCTCATTCACTCATCTGCGAAAGTG 
 Homo_sapiens  ACCTCCTCACACTCACTCATCTG---------------------------TGAGAAAGTA 
            NF-kBp50 
 Mus_musculus  TGAGAGCAAGAAACCCCAGGCTGGAGCTGCAGCT---CTTGGGACCTACGTGGGGGTCCC 
 Homo_sapiens  CAAAAGCAAGAGAAAGCTGGCTTGGGGTGGCACTCAACAGGTGCTCTGAGTGGCACCCAC 
                                              +1 
 Mus_musculus  TGCTGGGTCTCCAGATCTGGATACAGAATAGCCAGGAC----AAGGCTCCACAAGACCCT 
 Homo_sapiens  GGCCAGGTCCTGGGAGA-GGACAGAAAACAACTGGGACTCCTCAGCCCCCGGCAGCTCCC 
 
 Mus_musculus  GGGGCCCAGCGGCTGACAA-ATGACAGTGAGTGTAACTTCCTTTGTTGTTTTACTTCAGA 
 Homo_sapiens  AGTGCCCAGCCACCCACAACACAACCGTGA--GTAGCTTTTTTTGTTG-TTTATTTTAGG 
 
B. Exon 2 alignment                                                              NF-kB,c-REL 
 Mus_musculus  .ATGGGGGGGGGGTATTGTTATTGTCTCTTCACAAGTGAGAAGAGGGACTTGCCCAAAGT 
 Homo_sapiens  ............................................................ 
 
 Mus_musculus  CACATGATGAGAGTGACAGCATTGGACCCAGAGCAGCTACTTATACATCAAACACATCCT 
 Homo_sapiens  ............................................................ 
              STAT6 +1           STAT6             STAT6 
 Mus_musculus  TGCCCTAGAAATAGGTCTTCTAGAAGGCACCCATGTGACTTGCAGAGGGTATCTCTATCT 
 Homo_sapiens  ...................................TGACTCCGAAAGGG-ATTTCTATCT 
           STAT6             NF-kB,p65,c-REL 
 Mus_musculus  TC-----GTGGAGACAGGGAGCCGGGCTTCCTGTTGCTGTGTGCATCCTGTTGTTCTCTT 
 Homo_sapiens  GTCGAAAGGGAAGACAGGGAGCTGGGTTTCCTGTTGCTCTGTGCGTCCTGACGTTGGCTT 
 
 Mus_musculus  GTTAGGATGTCCAT-CAAATGCATGCATTTCCTTTCCT----AACTCTGGACAGTAACAG 
 Homo_sapiens  GTTAAGACCTGCATCCAAATGCCCATATTTCCTGCCCTTACCTACTTTGGTTAATAACCA 
 
 Mus_musculus  T---CGTCTGCGGCCAAGCTGTGCCTGAATGAGCAGAGGCACAGGCACCAGCCGTGGCCA 
 Homo_sapiens  CGCATGTTGGTGGCCATGCCGGGGCTAGGT-----GAGGCCCAAA-GCCAGCCACCGCCA 
 
 Mus_musculus  CCCAGCAAACATCTCT--------GCTGACTCAGACTGGGGTAAGGCATTCCCTAACAGT 
 Homo_sapiens  CCC--CCAACATCCCTCTTCTAGGGTGGATTCTACATGGAGTAAGCCATATCTTGAC... 
Figure 15. ClustalW Alignment of the Mouse and Human Putative 
Promoters.  Nucleotides highlighted in blue represent the conserved regions 
of mCnr2 and hCNR2 enabled prediction of the promoter region and cis-
sequences (labeled and underlined). The 5’ RACE TSSs (+1) are bold and 
purple nucleotides represent the 5’ UTR exons.    
55 
 
Cloning of the Putative Cnr2 Promoters 
 From the bioinformatics analysis, the regions surrounding the 
TSSs for mouse exons 1 and 2 appeared to have core promoter 
elements, as well as enhancer elements, therefore we wanted to 
evaluate these regions for promoter activity. To test for promoter 
activity, we used genomic DNA from purified B cells to PCR amplify 
select regions of exon 1 (Figure 16A) spanning -359 bp to +205 bp of 
exon 1a TSS (+1) as well as the region from -189 bp to +205 bp of 
exon 2 TSS (+1). During PCR amplification, the Taq polymerase adds 
an adenosine nucleotide at the end of elongation thereby creating an 
A-tail that can be easily cloned into a TA-cloning vector, such as the 
TOPO-blue vector. Therefore, the PCR amplified DNA fragments were 
gel purified and initially TA-cloned into the TOPO-blue vector then sub-
cloned into the pGL3-enhancer vector via the Hind III site by standard 
methods (Figure 16B). PCR screening was performed to determine 
insertion of the Cnr2 clones into the pGL3-enhancer vector (Figure 
16C). In total, three exon 1; pGL3-E16(-270,+205), E19(+68,+205), 
and E25(-359,+63) as well as five exon 2; pGL3-P7(-189,+36), P8(-
90,+36), P10(+13,+205), P11(-189,+101), and P13(-25,+101) 
experimental Cnr2 clones were chosen for evaluation of promoter 
activity.  
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Figure 16. Cloning of the Exon 1 Promoter. A. PCR amplification of Cnr2 
promoter regions TA-cloned into the TOPO-blue vector. B. Hind III digest of 
TOPO- Cnr2 clones for sub-cloned into the pGL3-enhancer vector. C. PCR 
amplification of Cnr2 clones in the pGL3-enhancer vector. 
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Determination of Cnr2 Promoter Activity in B cells 
 The pGL3- Cnr2 constructs were transfected by electroporation 
into IL-4/anti-CD40 stimulated primary B cells and 24 hrs later 
luciferase activity was determined for each construct. For exon 1 five 
constructs were analyzed, two control and three experimental vectors. 
The pGL3-enhancer vector does not have a promoter and contains only 
the SV40 enhancer downstream of the luciferase gene and therefore 
served as baseline activity. The pGL3-control vector contains both the 
SV40 promoter and enhancer and therefore exhibits full promoter 
activity. The pGL3-E25 experimental vector spans the region -359 bp 
to +63 bp (exon 1a, TSS +1) and contains all the TSSs and core 
promoter elements for exons 1a and 1b. The pGL3-E16 experimental 
vector spanning -270 bp to +205 bp contains the core promoter of 
exon 1a and a portion of the exon 1b core promoter. The GAGA-box 
and 1 TSS at -280 bp were excluded. The pGL3-E19 experimental 
vector spans from +68 bp to +205 bp and therefore did not contain 
either the exon 1a or exon 1b TSSs and core promoter cis-elements. 
Luciferase activation analysis for the exon 1 putative promoter 
demonstrated significant promoter activity for the pGL3-E25(-
359,+63), pGL3-E16(-270,+205) and pGL3-control vectors, but not 
for pGL3-E19(+68, +205), indicating that the RACE TSSs we identified 
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were in Cnr2 genomic regions that exhibited characteristics of a gene 
promoter (Figure 17A). In addition, pGL3-E25 had greater promoter 
activity then pGL3-E16 indicating that the GAGA-box and possibly the 
TSS at -280 bp are important for full promoter activity under these 
conditions.  
The five exon 2 experimental clones used to evaluate promoter 
activity were pGL3-P11, which spans the genomic region -189 bp to 
+101 bp (exon 2, TSS +1) and contained the core and enhancer cis-
elements. The truncated pGL3-P7 spanned -189 bp to +36 bp, was 
designed to exclude the 3’ NF-kBp65, cREL cis-elements yet contained 
the core and 5’ enhancer cis-elements. The pGL3-P8 was further 
truncated at the 5’end to span -90 bp to +36 bp and contained only 
core promoter cis-elements along with the 5’ cREL enhancer cis-
element. The pGL3-P13(-25,+101) truncated at the 5’ end to include a 
third of the TATA-box and 3’ core and enhancer cis-elements. The 
pGL3-P10(+13,+205) clone truncated at the 5’ end to exclude the 
TATA-box and INR core cis-elements, but extended at the 3’ end to 
include a portion of the GenBank designated exon 2 sequence. The 
reporter assay for the exon 2 clones demonstrated that the core 
promoter vector pGL3-P8 was sufficient to produce significant 
promoter activity. However, increased promoter activity was seen with 
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the pGL3-P7 clone, which contained the 5’ Sp1 cis-element as well as 
the pGL3-P11 clone that contained the 5’ Sp1 and the 3’ NF-kBp65, 
cREL cis-elements. No significant promoter activity was observed for 
either the pGL3-P10 or -P13 clones demonstrating that the TATA-box 
as well as the INR are needed for full promoter activity (Figure 17B). 
In all, these results demonstrated that the Cnr2 genomic region 
containing the TSSs as well as core promoter cis-elements for exons 
1a, 1b and 2 contained strong promoter activity as judged by these 
luciferase expression studies. 
 
 
 
 
 
 
60 
 
A. +1
exon 1b
TSSs
exon 3ORFexon 1a
+68
+205-359 +68+31-25 +10
+1
-270
-270
SV40P
+205
+63
+205
-359
L+ E
L+ E
L+ E
L+ E
L+ E
0 20 40 60 80
E16
E25
E19
*
*
*
 
B.
P11
P7
P8
P13
P10
-90
+13 +205
+101
-189
-25
+101
+36
+36-189
0 5 10 15
+252+205+101+70+25-21-90-189 +11
+1
SV40P L+ E
L+ E
L+ E
L+ E
L+ E
L+ E
L+ E
exon 3ORFexon 2
+1
*
*
*
*  
 
STAT6
Key: INRTATA-box DCE DPE
NF-Kb, p50
GAGA-boxCORE ELEMENTS;
ENHANCERS; p65 cREL Sp1 Elk-1
 
 
Figure 17. pGL3-Cnr2 Luciferase Activity in IL-4/anti-CD40 Activated 
B Cells. A. Exon 1 putative Cnr2 promoter pGL3-clones. B. Exon 2 putative 
Cnr2 promoter pGL3-clones. 
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Aim 3. To Determine CB2 Transcript Usage in Activated B Cells  
as well as Other Immune Cell Subtypes 
 
CB2 Transcript Expression in Mouse Activated B cells 
 Since CB2 is abundant in B cells and implicated in the 
involvement of various B cell functions, an understanding of transcript 
usage under varying conditions of B cell activation is of interest. The 
literature shows that stimulation of B cells with anti-CD40 and/or IL-4, 
through STAT6 (cis-sequence found in both CB2 putative promoter 
regions) activation, increases CB2 expression (8) (25) (42), whereas, 
LPS stimulation suppresses expression (26). LPS through TLR4 triggers 
an intracellular signaling cascade, similar to anti-CD40/CD40 binding, 
that activates the trans-regulatory factors Elk1 and NF-kB (found in 
the CB2 putative promoters). Both IL4/anti-CD40 and LPS promote B 
cell maturation and isotype switching. 
 Therefore, to gain a better understanding of CB2 transcipt usage 
in activated B cells, we stimulated primary B cells with either LPS ornd 
the co-stimulatory molecule anti-CD40. To determine the relative 
expression of the CB2 transcript variants, total RNA was collected at 1, 
3, and 8 hrs following stimulation for RT-qPCR analysis. We looked at 
the expression of the CB2 coding exon (exon 3, Figure 18A) and 
observed a steady increase over time following LPS stimulation. 
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Furthermore, using exon-specific primers and taqman probes revealed 
that LPS induced significant expression of the non-coding exon 1b and 
2 transcripts, whereas, the exon 1a transcript remained at baseline 
(Figure 18B).  
 B cells activated by IL-4 and anti-CD40 undergo class switch 
recombination (CSR) changing the C region of the H chain to switch 
from IgM to IgE. Our lab has previously shown that IL4/anti-CD40 
stimulation increased CB2 expression in B cells at the message (25) 
and protein level (1). In addition to this, our lab has also shown that 
co-treatment of the IL-4/anti-CD40 stimulated B cells with the CBR 
agonist CP55940 increased immunoglobulin class switching to IgE.  
 To determine the effective dose of IL-4, we initially looked at CB2 
the coding exon 3 expression using two concentrations of IL-4 (3 and 
10 ng/ml) with anti-CD40 (0.5 μg/ml). Exon 3 expression was 
significantly higher in B cells stimulated with 3 ng/ml of IL-4 compared 
to B cells stimulated with 10 ng/ml (Figure 19A). Therefore, we used 
the 3 ng/ml concentration of IL-4 with anti-CD40 to investigate CB2 
transcript variant expression. Following stimulation exon 3 increased 
within the first hour and maintained a steady state of expression 
thereafter (Figure 19A). On the other hand, non-coding exon 
expression increased increased 1 hr following stimulation with exon 2 
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continuing to increase over time, while the exons 1a and 1b returned 
to baseline by three hrs post stimulation (figure 19B). These results 
demonstrated for the first time that CB2 transcript usage differs in B 
cells depending upon the state of activation of the cell with exon 1a 
predominating under basal conditions and exons 1b and 2 under 
varying conditions of activation.  
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Figure 18. LPS Induces the Expression of the CB2 Exon 1b and 2 
Transcripts in Primary B cells. Primary B cells were cultured for 1, 3, and 
8 hrs in RPMI medium containing 5 μg/ml LPS. Total RNA was isolated and 1 
μg was used for RT-qPCR A. Total CB2 message expression (exon 3) 
increases over time with LPS stimulation. B. Exon 1b and 2 transcripts 
expression is significantly increased overtime whereas the exon 1a transcript 
remains at baseline. Results were obtained by the 2-ΔΔCT method in which β-
actin is the endogenous control and un-stimulated B cells (time 0) as the 
calibrator. Data are means ± S.E.M. of three independent experiments. * 
Significance at P = 0.05    
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Figure 19. Primary B cells Stimulated with IL4 and anti-CD40. Primary 
B cells were cultured for 1, 3, and 8 hrs in RPMI medium containing IL-4 and 
500 ng/ml anti-CD40. Total RNA was isolated and 1 μg was used for RT-qPCR 
A. Total CB2 expression (exon 3) significantly increases with 3 ng/ml 
compared to 10 ng/ml IL-4 and 500 ng/ml anti-CD40. The exon 2 transcript 
steadily increases with stimulation of 3 ng/ml IL-4. 
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CB2 Transcript Expression in Immune Cell Subtypes 
 The bioinformatics analysis performed in Aim 1 of the GenBank 
CB2 clones suggested that expression of the first 5’UTR exon (1 and 2) 
variants could be related to tissue or cell type, the clones of immune 
tissue expressed exon 1, and other tissue types expressed exon 2.  In 
spite of this, 5’ RACE showed that B cells expressed CB2 transcripts 
containing two variants of exon 1 and a single exon 2 variant. Since 
the previously described GenBank clones were obtained from immune 
tissues, and provided no information on transcript expression in 
immune cell subtypes, we wanted to investigate CB2 expression in 
other immune cells other than B cells. Total RNA was isolated from 
purified un-stimulated T cells, dendritic cells, and macrophages for 5’ 
RACE analysis. The results showed that CB2 transcript expression was 
unique to immune cell subtypes. For example, T cells expressed only 
the exon 1a variant, whereas dendritic cells and macrophages 
expressed two transcript variants (exon 1a and 2). Most interesting 
was that the exon 1b variant was only observed in B cells (Figure 20). 
To confirm the expression of the transcript variants in the immune cell 
subtypes, RT-qPCR using exon specific primers and taqman probes 
was done (Figure 21). Coding exon 3 transcript expression was highest 
in B cells, followed by dendritic cells, then macrophages and T cells 
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expressing the least (Figure 21A). The exon 1a variant was the major 
CB2 transcript seen in T cells. Dendritic cells and macrophages 
expressed both the exon 1a and 2 variants, however the relative 
expression of exon 2 was much higher in the dendritic cells (Figure 
21B). The expression of the exon 1b variant was exclusive to B cells, 
though a negligible amount was observed in dendritic cells, which 
could be from amplification of residual genomic DNA. These results 
showed for the first time that the CB2 transcript expression profile is 
different among the immune cell subtypes and that variant expression 
could be related to cell type and/or cell function. In addition, among 
these immune cell subtypes, the exon 1b variant was observed only in 
B cells and therefore could potentially be a cell specific target for CB2 
expression in this cell type. 
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Figure 20. Immune Cell Subtypes 5’ RACE CB2 Transcripts. Gel 
electrophoresis of the RACE products isolated from Splenocytes, B cells , T 
cells (top panel) dendritic cells and macrophages (bottom panel).  
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Figure 21. Quantitative RT-qPCR of the CB2 Transcripts in Immune 
Cell Subtypes. Using 1 μg of total RNA isolated from un-stimulated B cells, T 
cells, Dendritic cells (DC) and macrophages (Mo) CB2 transcript usage was 
determined. A. Total CB2 expression (exon 3) in the immune cell subtypes. 
B. CB2 transcript expression in the immune cell subtypes. 
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CB2 Transcript Expression in Development of B cells  
 In A recent study investigating CB2 mediation of immature B cell 
retention in bone marrow sinusoids (37) showed a two-fold higher 
expression of CB2 in immature B cells compared to pre-B cells and that 
CB2 deficiency led to a lower frequency of the Ig light -chain (λ+) 
immature and mature B cells in the blood and spleen, thus suggesting 
a role for CB2 in the formation of the B cell repertoire.  In addition the 
results above have shown that expression of the CB2 transcript 
variants can be related to immune cell subtype as well as the 
activation state of B cells. Therefore, we investigated CB2 transcript 
expression in three different B cell lines representing B cell 
development from the pre-B stage to the mature stage.  
  The three mouse B cell lines used were; 18.81, an Abelson 
virus-transformed pre-B cell line that synthesizes only H chain, no light 
chain is produced. WEHI-231, an immature B lymphoma cell line that 
lacks Fc receptors and expresses only surface IgM and not IgD. K46μ, 
a mature B lymphoma cell line that expresses surface IgM and IgD. 
The 5’ RACE of the different cell lines showed that the pre-B cell line 
expressed the exon 1a transcript and that the immature B cell line 
WEHI-231 and the mature B cell Line K46μ express all three 
transcripts but at different levels (Figure 22A). Therefore, we 
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performed RT-qPCR to determine the predominant CB2 transcript 
expressed in these B cell lines. CB2 coding exon 3 was observed to be 
the highest in WEHI-231 (immature) and lower in 18.81 and K46μ. 
The predominant CB2 transcript observed in 18.81 and WEHI-231 was 
the exon 1a transcript, whereas the exon 1b transcript was 
predominant in the mature K46μ B cell line (Figure 22B). The data 
suggested that expression of the CB2 transcript variants could be 
related to the developmental stage of B cells. In addition these results 
further support that CB2 transcript usage varies in response to changes 
in B cell biology. 
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Figure 22. CB2 Transcript Expression in B Cell Lines. A. Gel 
electrophoresis of the 5’ RACE products present in the B cell lines. B. RT-
qPCR for CB2 transcript expression in the B cell lines. 
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DISCUSSION 
 
The relative robust expression of CB2 in human and mouse B 
cells suggests that this receptor may have an important role in B cell 
biology. However, only a few reports have investigated the function of 
CB2 in B cells. Furthermore, examination of the CB2 transcript 
expression and Cnr2 regulatory elements (i.e. promoter and TSS) in B 
cells had not been reported. Therefore, we investigated the genomic 
sequences involved in transcription of CB2 by identifying the TSSs, 
mRNA transcripts and core promoter regions in purified resting and 
activated mouse B cells.  
Our data provide the first evidence that resting splenic B cells in 
mice use multiple TSSs and express at least three CB2 transcript 
variants. Based on present models of transcription initiation it is 
possible that two mechanisms of transcription could be involved in the 
generation of these variants: 1) alternative splicing of the 5’UTRs in 
the case of exons 1 or 2, and in fact donor-acceptor sites occur in 
these regions; and 2) alternative transcription initiation (dispersed 
initiation, see below) generating exon 1 variants that differ in the 
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length of their 5’ ends. The latter event may have occurred in the case 
of exon 1 in that we observed different lengths of the 5’ ends ranging 
over 295 bps and containing a cluster of four TSSs. Interestingly, a 
cluster of TSSs was predicted by the database, DBTSS, in the 5’ 
flanking regions of exons 1 and 2; furthermore, multiple TSSs were 
reported in GenBank CB2 clones from various tissues in these same 
regions. Our RACE products from B cells identified new TSSs for exons 
1 and 2 that were not only different than reported in other tissues but 
for the most part longer at the 5’ ends. Because of these many TSSs 
spread over hundreds of bps, we analyzed for core promoter 
sequences in these areas using an in silico approach.  Interestingly, we 
found consensus core promoter sequences such as INR, DPE, DCE 
along with either TATA or GC boxes in abundance and in proximity to 
all of the TSSs expressed in mouse and the one TSS expressed in 
human B cells (see Figure 14). However, although present, these 
sequences were in different numbers and relative distances to the TSS 
position suggesting heterogeneity in core promoter activity under 
resting and activated conditions. Although the functional significance of 
multiple TSSs and core promoters is unknown, previous studies 
suggested this heterogeneity relates to cell type and/or cell activation 
state. This was observed in studies on the control of alternative first 
75 
 
exons of the glucocorticoid receptor (GR) which are under the control 
of specific transcription factors that control both tissue specific and cell 
activation state specific GR expression (49). This was also observed 
with adenosine A2A receptor (A2AR) 5’UTR splice variants wherein the 
long 5’UTR A2AR variants were observed in resting PMNs, whereas the 
short 5’UTRs were expressed to a greater extent in LPS- stimulated 
cells suggesting short 5’UTR variants were more efficiently translated 
(23) and suggesting the length of the 5’UTR can be a factor in 
determining tissue specificity and cell activation state. 
In our mouse CB2 studies, different TSSs and transcript 
expression were observed in different cell types. For example, resting 
T cells expressed only the exon 1a variant (Figures 20 & 21) and 
variants of this have been reported in thymocytes, splenocytes, and 
the macrophage like cell line, NFS107 (GenBank accession nos. 
AK037898, X86405, and NM009924). Whereas, bone and liver tissue 
(GenBank accession nos. BC024052 and AK036658) expressed the exon 
2 variant though shorter at the 5’end than what was observed in B 
cells. Besides T cells, variation of CB2 transcript expression was 
observed in other immune cell subtypes. For example, purified 
dendritic cells and macrophages expressed the exon 1a and 2 
variants(Figure 20), though in dendritic cells the expression of the two 
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variants was more or less equal, whereas in macrophages the exon 1a 
variant was expressed five-fold higher than the exon 2 variant (Figure 
21). Furthermore, resting splenic B cells expressed 3 CB2 transcripts 
with an expression rank order of exon 1a > exon 2 > exon 1b, and of 
interest expression of the exon 1b variant was only observed in B cells 
(Figures 13 and 21). This variation in transcript expression among the 
various subtypes may be accounted for by variations in core promoter 
activity surrounding the different TSSs.  
In contrast to the multiple TSSs and transcript variants we saw 
in mouse cells, human peripheral B cells collected from three different 
donors expressed a single CB2 transcript and TSS (Figure 7). 
Interestingly, our observations in mouse and human are in line with 
those showing that two different strategies are employed by Pol II for 
transcription initiation. The hCNR2 appears to utilize the more common 
strategy termed “focused initiation” in which a single TSS and the core 
promoter contains a TATA-box, BREd, INR, and DPE. On the other 
hand, the mCnr2 is more like the second strategy that involves 
multiple weak TSSs dispersed over DNA regions of approximately 50 to 
150 bps, thereby dubbed “dispersed initiation” (21). The mechanisms 
of dispersed initiation are not clear but probably involve selective 
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usage of multiple upstream and downstream recognition and promoter 
elements similar to what we observed surrounding the mouse TSSs.       
Different mCB2 transcripts are not only associated with different 
cell types but also with different cell activation states. Using RT-qPCR, 
we showed that the mouse exon 1a transcript was predominantly 
expressed in resting splenic B cells (Figure 13) but that exons 1b and 
2 were more pronounced in the LPS-activated B cells (Figure 18B), and 
that exon 2 increased in IL-4/anti-CD40 stimulated B cells (Figure 
19B). A possible explanation of the observed variation in CB2 transcript 
expression is the presence of proximal regulatory cis-sequences to the 
transcript TSS. Because in addition to core promoter activity, cell 
activation can lead to gene transcription through enhancer elements 
on the DNA either 5’ or 3’ to the core promoter region (5). 
Interestingly, the in silico analysis performed in Aim 2 identified 
proximal NF-kB (-82 and +72 bp) as well as STAT6 (-6 and +12 bp) 
cis-sequences 5’ and 3’ of the TSS(+1) for exon 2 (Figure 15B), which 
may account for the observed increase expression of the exon 2 
variant in B cells activated by LPS or IL-4/anti-CD40 since it is well 
known that LPS, IL-4 and anti-CD40 activate B cells through an 
increase in NF-kB (12, 44, 47) and with IL-4 through activation of 
STAT6. In addition, pGL3-Cnr2 reporter plasmid transfected mouse B 
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cells containing exon 2 genomic DNA constructs spanning -189 to 
+101 bp showed strong promoter activity when stimulated with IL-4 
and anti-CD40 antibodies (Figure 17B); non-stimulated cells showed 
little luciferase activity (data not shown). Which the 5’ NF-kB cis-
sequence appears to be important for promoter activation, because 
constructs in which the 3’ NF-kB site has been omitted still exhibit 
strong promoter activity (Figure 17B), in contrast to the much lower 
activity observed reporter constructs in which the 5’ NF-kB site has 
been deleted (Figure 17B). Furthermore, it is In addition to NF-kB, 
STAT6 binding might also be involved in the significant increase of the 
exon 2 transcript observed in B cells stimulated with IL-4/anti-CD40, 
because two putative STAT6 sites are located at -6 and +12 bp of the 
TSS(+1) of exon 2 (Figure 15B). However, as reported previously 
(Thieu 2007), NF-kB may be required for binding of STAT6, supported 
by the minimal to no promoter activity observed in the exon 2 reporter 
constructs in which one or both STAT6 sites are present but the 5’ NF-
kB site has been deleted (Figure 17B). However, further analysis is 
required to determine the Cnr2 regulatory relationship of these cis-
sequences for the trans-factors under these conditions in B cells.   
In addition to the variation of CB2 transcript expression seen in 
activated B cells, differences in CB2 transcript expression was also 
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observed in B cell development. RACE and RT-qPCR analysis of CB2 
transcript expression in three mouse B cell lines representing different 
stages of development showed that pre-B cells expressed only the 
exon 1a variant, whereas immature and mature B cells express all 
three variants, though at varying levels. Expression of the transcript 
variants was greatest in the immature B cells, notably the exon 1a 
variant, whereas mature B cells expressed mainly the exon 1b variant 
(Figure 22). Our results are in line with a recent report in which CB2 
transcript expression was higher in immature B cells located in bone 
marrow sinusoids when compared to other developmental stages and 
suggested a function for CB2 in the formation of the B cell repertoire 
(Pereira 2009).  
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SUMMARY 
 
 In summary, we have characterized for the first time multiple 
TSSs that define alternative CB2 transcripts in mouse splenic B cells as 
well as a single TSS and transcript in human PBMC B cells. We were 
able to confirm by RT-PCR primer mapping, the relative location of the 
TSS for mouse exons 1b and 2, as well as the human exon 1. These 
experimentally defined TSSs directed further in silico analysis and 
showed that these regions contain consensus sequences for multiple 
elements such as TATA-box, INR and DPE. These elements were found 
at the expected distances from the TSSs and by reporter assay 
experiments these segments contained significant promoter activity 
inferring that we correctly identified several of the TSSs in mouse B 
cells as well as identify the location of two promoters. In addition, we 
identified CB2 transcript usage in resting B cells as well as other 
immune cell subtypes, in which the exon 1b transcript appears to be 
unique to B cells and therefore may serve as a therapeutic target in B 
cells. In addition, CB2 transcript expression was different in the mouse 
B cell lines representing various maturation stages.  Furthermore, we 
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identified CB2 transcript expression in LPS and IL-4/anti-CD40 
activated B cells, in which the exon 1b and exon 2 variants appear to 
be important.  
 The stimuli used in this study are known inducers of class switch 
recombination (CSR) and previous work done in our lab has suggested 
a role for CB2 receptor activation in enhancing IL-4/anti-CD40 CSR 
from IgM to IgE, therefore it is possible from our work here, that exon 
1b transcripts are unique to B cells and therefore provide a gene 
target for suppressing CB2 expression in only B cells and not other 
immune cell subtypes. The identification of the CB2 transcripts 
expressed during these conditions will guide future studies in 
regulating this receptor at the gene level, and provide possible gene 
targets(i.e. RNA silencing) for the therapeutic application in 
suppressing CB2 and IgE production in Allergic diseases.   
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